TP53 and EGFR Mutational Status in Thymoma: A Genetic Sequencing Study

Abstract

Thymoma staging, histologic type, and complete eradication through any treatment modalities are significant to increase the survival of patients and reduce its recurrence rate. Prognosis of thymoma is worse at higher stages of the disease. The patients at the advanced stage of the thymoma have a 5-year median survival of 69%. Currently, the treatment choice in thymoma is surgery providing a better prognosis (Detterback et al.,

The Molecular Landscape of Thymic Epithelial Tumors: A Comprehensive Review

“…TP53 Exon 6 mutations, including both missense and nonsense mutations, were also detected only in 7.4% of cases. Both results suggest a limited role of EGFR and TP53 in the pathogenesis of thymomas [8]. TP53 mutations, however, seem to be prominent in TCs, especially in their highly aggressive forms [9].…”

“…The key tumor-suppressor genes, P53 (TP53) and EGFR, commonly mutated in human cancers, have also been scrutinized in thymomas. A recent study by Syahruddin et al identified EGFR Exon 18 mutation (E709K) and a nonsense mutation in a small subset of 7.4% of cases [8]. TP53 Exon 6 mutations, including both missense and nonsense mutations, were also detected only in 7.4% of cases.…”

“…Numerous NGS investigations have recently tried to comprehensively explore the genetic foundation of TETs [6][7][8][9][10][11][12][13][14][15][16][17][18][19][20][21][22][23]. Due to the rarity of TETs, only limited studies have collected high-throughput sequencing datasets.…”